Immugenia is proud to have been selected to participate on February 22, 2024 at the Johnson & Johnson Inaugural Gene Therapy Summit in San Francisco! We were selected to showcase our technology to the west coast community of gene therapy development.

Thursday, February 22, 2024

Share

Immugenia is proud to have been selected to participate on February 22, 2024 at the Johnson & Johnson Inaugural Gene Therapy Summit in San Francisco! We were selected to showcase our technology to the west coast community of gene therapy development.

Thursday, February 22, 2024

Share

Immugenia is proud to have been selected to participate on February 22, 2024 at the Johnson & Johnson Inaugural Gene Therapy Summit in San Francisco! We were selected to showcase our technology to the west coast community of gene therapy development.

Thursday, February 22, 2024

Share

About the J&J event where Immugenia was invited to present

Cell and gene therapies (CGTs) harness the power of a patient’s own immune system to treat or, in some cases, even cure a variety of previously untreatable diseases. Currently, the market size is estimated at 18.12B, with projected growth to 82.24B by 2032.1 The explosive growth can be primarily attributed to the significant increase in FDA-approved treatments over the past 2 decades. In 2024 alone, as many as 31 gene therapy launches are expected including more than 29 adeno-associate virus (AAV) therapies.

Kathie Béland, (Research Director – Immugenia) presenting Immugenia’s technology at J&J Inaugural Gene Therapy Summit in San Francisco.

About the J&J event where Immugenia was invited to present

Cell and gene therapies (CGTs) harness the power of a patient’s own immune system to treat or, in some cases, even cure a variety of previously untreatable diseases. Currently, the market size is estimated at 18.12B, with projected growth to 82.24B by 2032.1 The explosive growth can be primarily attributed to the significant increase in FDA-approved treatments over the past 2 decades. In 2024 alone, as many as 31 gene therapy launches are expected including more than 29 adeno-associate virus (AAV) therapies.

Kathie Béland, (Research Director – Immugenia) presenting Immugenia’s technology at J&J Inaugural Gene Therapy Summit in San Francisco.

About the J&J event where Immugenia was invited to present

Cell and gene therapies (CGTs) harness the power of a patient’s own immune system to treat or, in some cases, even cure a variety of previously untreatable diseases. Currently, the market size is estimated at 18.12B, with projected growth to 82.24B by 2032.1 The explosive growth can be primarily attributed to the significant increase in FDA-approved treatments over the past 2 decades. In 2024 alone, as many as 31 gene therapy launches are expected including more than 29 adeno-associate virus (AAV) therapies.

Kathie Béland, (Research Director – Immugenia) presenting Immugenia’s technology at J&J Inaugural Gene Therapy Summit in San Francisco.

To that end, Johnson & Johnson Innovation launched the Gene Therapy QuickPitch Poster Session. Innovators from across the globe were invited to share novel therapeutic approaches to gene therapy, emphasizing delivery, editing, and immune-mitigation for the chance to showcase their innovation in a live poster session.

The live poster session was held at the Gene Therapy Summit on February 15 in Brisbane, CA. Selected finalists showcased their science to gene therapy R&D leaders from Johnson & Johnson and the external ecosystem.

To that end, Johnson & Johnson Innovation launched the Gene Therapy QuickPitch Poster Session. Innovators from across the globe were invited to share novel therapeutic approaches to gene therapy, emphasizing delivery, editing, and immune-mitigation for the chance to showcase their innovation in a live poster session.

The live poster session was held at the Gene Therapy Summit on February 15 in Brisbane, CA. Selected finalists showcased their science to gene therapy R&D leaders from Johnson & Johnson and the external ecosystem.